Press Releases

Major General, U.S. Army, Retired Bob Dees Joins N Brereton Medical Technologies

Exciting Announcement:
Major General, U.S. Army, Retired
President, National Center for Healthy Veterans [www.healthyveterans.org]
Author, The Resilience Trilogy,
Joins N Brereton Medical Technologies Board of Advisors as Strategic Advisor; United States Military Support

N Brereton Medical Technologies is honored to announce that General Bob Dees, President of the National Center for Healthy Veterans, has joined our Board of Advisors. A distinguished leader with a lifetime of service in the United States Army, General Dees brings unparalleled awareness and passion to our mission of revolutionizing the fight against addiction to bring an off-ramp to drug use within the military and throughout the nation.

General Dees, renowned for his commitment to the well-being of veterans and communities, has been instrumental in shaping initiatives that empower individuals to reclaim their health and purpose. His leadership at the National Center for Healthy Veterans reflects his unwavering dedication to human dignity and freedom—a mission that resonates deeply with our company’s vision.

In his new role, General Dees will lend his strategic insight and leadership to advance the development and military patient use of FenBlock, N Brereton’s groundbreaking solution for those seeking or through their physician’s encouragement to safely recapture their health from fentanyl and opioid dependence and use. FenBlock’s patented graduated titration technology awaiting FDA (pre-clinical) clearance offers a needed structured, safer path to sobriety—marking as Gen. Dees states; “a monumental contribution to humankind.”

“FenBlock embodies hope, healing, and renewal,” says General Dees. “The technology represents a bold, unprecedented step toward liberation from the chains of opioid addiction. I am honored to support this inspiring mission, knowing the transformative impact it will have for countless individuals and families.”

This partnership aligns with General Dees’ lifelong work—restoring lives, fostering community, and helping people find lasting freedom. Together, N Brereton Medical Technologies and General Dees aim to pave the way for a new chapter in the military’s fight against addiction, offering a beacon of hope to veterans and all those battling substance dependence.

With General Bob Dees on board, N Brereton Medical Technologies is poised to amplify its impact, delivering life-changing solutions for those in need. The inspiring story of FenBlock is just beginning—and with leaders like General Dees alongside us, the future looks brighter than ever. Contact neil@FenBlockmed.com for further information.

N Brereton Medical Technologies Joins the Parenteral Drug Association (PDA)

N Brereton Medical Technologies Joins the Parenteral Drug Association (PDA) to Drive Innovation and Patient-Centered Solutions

N Brereton Medical Technologies is proud to announce our membership in the Parenteral Drug Association (PDA), www.pda.org the leading global provider of science, technology, and regulatory information. This partnership aligns with our mission to ensure that FenBlock—a combination novel medical device—is developed, cleared by the FDA, and prescribed with a commitment to best practices, innovation, and safe patient-centered solutions.

Our Commitment through PDA Membership

Through every stage of FenBlock’s design, from innovation to patient use, N Brereton Medical Technologies is guided by the principles of scientific excellence and regulatory rigor. Our partnership with PDA reflects our dedication to embedding the highest standards into FenBlock’s development, ensuring it provides safe, effective, and innovative solutions to help patients overcome fentanyl addiction.

About PDA

For 65 years, the PDA has been a trusted global leader in advancing science, technology, and regulation within the pharmaceutical and biopharmaceutical industries. PDA brings together technical experts, manufacturers, regulatory officials, and academic leaders to foster collaboration and knowledge sharing. Their mission is to develop scientifically sound, practical technical information to guide the future of pharmaceutical products and manufacturing science.

PDA’s Mission and Vision

Mission: To provide scientifically sound, practical technical information and resources that advance science and regulation for the pharmaceutical and biopharmaceutical industries through the expertise of its global membership.

Vision: To be the foremost global provider of science, technology, and regulatory information and education for the pharmaceutical and biopharmaceutical industry.

With over 10,500 individual members worldwide, PDA draws on the expertise of its members to influence industry practices, shaping the future of pharmaceutical technology through high-quality technical reports, conferences, and education. PDA’s efforts enable members to better serve patients through innovation and effective regulation.

N Brereton Medical Technologies’ Mission

At N Brereton Medical Technologies, we are committed to advancing pharmaceutical and biopharmaceutical science and regulation, ensuring that our products—such as FenBlock—reflect the latest industry standards and serve the best interests of patients. Our collaboration with PDA reinforces our mission to deliver innovative, safe, and patient-centered solutions at every step, from design to prescribed use.

We look forward to working closely with PDA’s network of experts, leveraging technical knowledge and regulatory insights to bring FenBlock to market and make a meaningful impact in the lives of patients battling fentanyl addiction.

N Brereton Medical Technologies Partners with Kymanox

N Brereton Medical Technologies Partners with Kymanox to Accelerate Development

and Commercialization of FenBlock

Forest, Virginia – March 1, 2024 – N Brereton Medical Technologies, a pioneering

company in health and wellness innovation, is thrilled to announce a strategic

partnership with Kymanox, a leading life science solutions partner headquartered in

Raleigh, North Carolina.

Kymanox brings to the table a diverse team of experts with a deep understanding of

the life sciences industry. With their unparalleled expertise and track record of success,

Kymanox is well-equipped to support N Brereton Medical Technologies in accelerating

the development, FDA clearance, and commercialization of FenBlock, a

groundbreaking medical device designed to combat the fentanyl and opioid epidemic.

"FenBlock represents a crucial advancement in addiction treatment, and we are

excited to partner with Kymanox to bring this innovative solution to market," said Neil

B. Jackson, Founder and CEO of N Brereton Medical Technologies. "Kymanox's

commitment to excellence and their proven track record make them the ideal partner

to help us navigate the complexities of the regulatory landscape and accelerate the

development and commercialization of FenBlock.”

Kymanox's Global Headquarters, located in Raleigh | Durham | RTP, NC, and

Morrisville, North Carolina, provide the perfect strategic base for collaboration between

the two companies. With access to top-tier talent and state-of-the-art facilities,

Kymanox is well-positioned to support N Brereton Medical Technologies throughout

the development process.

"We are thrilled to partner with N Brereton Medical Technologies to support the

development and commercialization of FenBlock," said Stephen Perry, Founder and

CEO of Kymanox. "At Kymanox, we pride ourselves on our ability to connect the dots

and provide end-to-end solutions that drive success. Together with N Brereton Medical

Technologies, we look forward to making a meaningful impact in the fight against the

fentanyl and opioid epidemic.”

About N Brereton Medical Technologies:

N Brereton Medical Technologies is a leading innovator in health and wellness,

dedicated to developing groundbreaking solutions to address fentanyl and opioid

healthcare challenges. With a focus on empowering patients and transforming lives, N

Brereton Medical Technologies is committed to driving positive change in the

healthcare industry.

About Kymanox:

Kymanox is a premier life science solutions partner, offering a comprehensive suite of

services to support the development, regulatory approval, and commercialization of

pharmaceuticals, biologics, medical devices, and combination products. With a team

of seasoned experts and a proven track record of success, Kymanox is trusted by

leading companies in the life sciences industry.

For more information about N Brereton Medical Technologies, please visit

www.fenblockmed.com

For more information about Kymanox, please visit www.kymanox.com.

Contact:

Neil B. Jackson

Founder and CEO

N Brereton Medical Technologies

434-509-2999

neil@fenblockmed.com

FENBLOCK™

PRESS RELEASES

Major General, U.S. Army, Retired Bob Dees Joins N Brereton Medical Technologies

N Brereton Medical Technologies Joins the Parenteral Drug Association (PDA)

N Brereton Medical Technologies Partners with Kymanox

PRESS RELEASES

Major General, U.S. Army, Retired Bob Dees Joins N Brereton Medical Technologies

N Brereton Medical Technologies Joins the Parenteral Drug Association (PDA)

N Brereton Medical Technologies Partners with Kymanox

This website uses cookies.